Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 332

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 332
---
ilex as the surviving   
 company in the Business Combination, and, after giving effect to such Business Combination, Legacy Scilex became a wholly owned subsidiary of Vickers and changed its name to “Scilex, Inc.”, and (ii) Vickers changed its name to                    
 “Scilex Holding Company”. Pursuant to the terms of the Merger Agreement, effective as of the closing of the Business Combination on November 10, 2022, outstanding equity awards under the Scilex Pharma 2017 Plan and 2019 Stock Option              
 Plan were adjusted as follows: (i) each option to purchase Legacy Scilex common stock that was outstanding as of immediately prior to the Effective Time was converted into the right to receive an option relating to our Common Stock upon          
 substantially the same terms and conditions as were in effect with respect to such option immediately prior to the Effective Time (the “Option”) except that (x) such Option relates to that whole number of shares of our Common Stock               
 (rounded down to the nearest whole share) equal to the number of Legacy Scilex common stock subject to such Option, multiplied by the Exchange Ratio of 0.673498:1 (the “Exchange Ratio”), and (y) the exercise price per share for each              
 such share of our Common Stock equals the exercise price per share of such Option in effect immediately prior to the Effective Time, divided by the Exchange Ratio (rounded up to the nearest whole cent). The numbers in the table reflect the share 
 numbers outstanding and exercise prices as of December 31, 2024, in each case after giving effect to the Exchange Ratio.                                                                                                                              |

| (2) | Options granted in 2019 and 2020 were granted under the 2019 Stock Option Plan, and options granted in 2023 
 were granted under the Equity Incentive Plan.                                                               |

| (3) | Options have fully vested. |

| (4) | Each option vested as to 1/4th of the shares subject to the option on the                                                                                                                                                       
 one-year anniversary of the vesting commencement date and 1/48th of the original number of shares subject to the option vested and shall vest on each monthly anniversary thereafter, subject to full                           
 acceleration in the event of an involuntary termination of employment without “cause” or due to a voluntary termination of employment with “good reason” (each, as defined in the applicable option agreement) within 13 months 
 following a Change in Control (as defined in the